Home > Insider Trading > Filing (0001209191-17-046036)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
873303	Sarepta Therapeutics Inc.	SRPT	Pharmaceutical Preparations (2834)	930797222

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1529297	T David Howton	215 First Street, Suite 415 Cambridge MA 02142	Svp, General Counsel	No	Yes	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Acquisiton	2017-07-20	19,056	$13.71	41,357	No	4	M	Direct
Common Stock	Disposition	2017-07-20	19,056	$41.00	22,301	No	4	S	Direct
Common Stock	Acquisiton	2017-07-20	5,944	$13.71	28,245	No	4	M	Direct
Common Stock	Disposition	2017-07-20	5,944	$41.00	22,301	No	4	S	Direct
Common Stock	Acquisiton	2017-07-21	324	$13.71	22,625	No	4	M	Direct
Common Stock	Acquisiton	2017-07-21	676	$23.85	23,301	No	4	M	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	M	Direct
No	4	S	Direct
No	4	M	Direct
No	4	S	Direct
No	4	M	Direct
No	4	M	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Non-Qualified Stock Options (right to buy)	Disposition	2017-07-20	19,056	$13.71	19,056	$13.71
Common Stock	Non-Qualified Stock Options (right to buy)	Disposition	2017-07-20	5,944	$13.71	5,944	$13.71
Common Stock	Incentive Stock Option (right to buy)	Disposition	2017-07-21	324	$13.71	324	$13.71
Common Stock	Incentive Stock Option (right to buy)	Disposition	2017-07-21	676	$23.85	676	$23.85

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
10,527	2017-02-28	2026-02-28	No	4	M	Direct
19,146	2017-02-28	2026-02-28	No	4	M	Direct
93	2017-02-28	2026-02-28	No	4	M	Direct
15,092	2013-11-05	2022-11-05	No	4	M	Direct

Footnotes

This transaction was effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person, on May 18, 2017, accordingly, the reporting person had no discretion with regards to the timing of the transaction.
Half of the options begin vesting in the event the FDA provides marketing approval for eteplirsen as of the applicable PDUFA date and the other half of the options begin vesting in the event Sarepta files a Marketing Authorization Application with the EMEA prior to December 31, 2016. Vesting of the options allocated to the achievement of each goal is as follows: (i) 50% of the options allocated to the achieved goal vests immediately upon achievement of the performance condition (25% of the total Performance-Based Options granted) and (ii) the remaining 50% of the options allocated to the achieved goal (25% of the total Performance-Based Options granted) vests over four years with 25% of these remaining options vesting on the first year anniversary of the grant date and 1/48th of these remaining options vesting monthly thereafter.
25% of the option became exercisable on the first anniversary of the date of hire (11/05/2012) and 1/48th of the total granted option became exercisable on each monthly anniversary thereafter, such that the option became fully exercisable on the fourth anniversary of the date of hire.